Pan-Histone Demethylase Inhibitors Simultaneously Targeting Jumonji C and Lysine-Specific Demethylases Display High Anticancer Activities
详细信息 查看全文
- 作者：Dante Rotili ; Stefano Tomassi ; Mariarosaria Conte ; Rosaria Benedetti ; Marcello Tortorici ; Giuseppe Ciossani ; Sergio Valente ; Biagina Marrocco ; Donatella Labella ; Ettore Novellino ; Andrea Mattevi ; Lucia Altucci ; Anthony Tumber ; Clarence Yapp ; Oliver N. F. King ; Richard J. Hopkinson ; Akane Kawamura ; Christopher J. Schofield ; Antonello Mai
- 刊名：Journal of Medicinal Chemistry
- 出版年：2014
- 出版时间：January 9, 2014
- 年：2014
- 卷：57
- 期：1
- 页码：42-55
- 全文大小：650K
- ISSN：1520-4804
文摘
In prostate cancer, two different types of histone lysine demethylases (KDM), LSD1/KDM1 and JMJD2/KDM4, are coexpressed and colocalize with the androgen receptor. We designed and synthesized hybrid LSD1/JmjC or 鈥減an-KDM鈥?inhibitors 1鈥?b>6 by coupling the skeleton of tranylcypromine 7, a known LSD1 inhibitor, with 4-carboxy-4鈥?carbomethoxy-2,2鈥?bipyridine 8 or 5-carboxy-8-hydroxyquinoline 9, two 2-oxoglutarate competitive templates developed for JmjC inhibition. Hybrid compounds 1鈥?b>6 are able to simultaneously target both KDM families and have been validated as potential antitumor agents in cells. Among them, 2 and 3 increase H3K4 and H3K9 methylation levels in cells and cause growth arrest and substantial apoptosis in LNCaP prostate and HCT116 colon cancer cells. When tested in noncancer mesenchymal progenitor (MePR) cells, 2 and 3 induced little and no apoptosis, respectively, thus showing cancer-selective inhibiting action.